IP Library › Patent Application 18256726
Patent Application
App. No. 18/256,726

HYDROGEL MICROPARTICLE-BASED LUBRICANT

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/256,726
Abstract

Methods for viscosupplementation in a joint or surgical site of a human or animal subject are disclosed along with unique materials for achieving such beneficial outcomes. The methods generally comprise introducing into the joint or surgical site a plurality of porous viscoelastic solid hydrogel microparticles having a size of greater than about 30 pm, and substantially free of any cells, tissue, or therapeutic compounds. Kits for viscosupplementation in a joint or surgical site of a human or animal subject are also disclosed. The kits comprise the plurality of porous viscoelastic solid hydrogel microparticles having a size of greater than about 30 pm, and substantially free of any cells, tissue, or therapeutic compounds, and instructions for administering the same.

Claims (32)

1 . A method for viscosupplementation in a joint or surgical site of a human or animal subject, said method comprising: introducing into the joint or surgical site a plurality of porous viscoelastic solid hydrogel microparticles having a size of greater than about 30 μm, and substantially free of any cells, tissue, or therapeutic compounds.

2 . The method of claim 1 , wherein said hydrogel microparticles are injected at or near the joint or surgical site.

3 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are characterized as self-sustaining bodies having a 3-dimensional matrix of covalently or ionically crosslinked polymer compounds.

4 . The method of any one of the foregoing claims, wherein said plurality of porous viscoelastic solid hydrogel microparticles comprise at least two different populations of microparticles, wherein a first population of microparticles comprises a plurality of microparticles having a first characteristic, and a second population of microparticles comprises a plurality of microparticles having a second characteristic, wherein said first characteristic is different from said second characteristic.

5 . The method of any one of the foregoing claims, wherein said hydrogel microparticles provide cushioning and/or reduce friction between tissues at or near the joint or surgical site.

6 . The method of any one of the foregoing claims, wherein said hydrogel microparticles induce a favorable physiological response in the subject at the site of implantation.

7 . The method of any one of the foregoing claims, wherein said hydrogel microparticles do not induce inflammation.

8 . The method of any one of the foregoing claims, wherein said hydrogel microparticles increase amount or quality of cartilage produced in a joint at the site of implantation.

9 . The method of any one of the foregoing claims, wherein said hydrogel microparticles provide a resilient response to load-bearing for cushion and reduce friction within a joint at the site of implantation.

10 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are introduced into a joint of the knees, hips, ankles, wrists, elbows, shoulders, toes, fingers, or spine.

11 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are injected into an intraarticular space of a joint.

12 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are introduced into a synovial capsule portion of said joint.

13 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are introduced in and/or around a site of implantation of a surgical device in said subject.

14 . The method of claim 13 , wherein said surgical device is surgical mesh.

15 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are introduced subdermally as a dermal filler.

16 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are introduced between organs of said subject.

17 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are suspended or dispersed in a suitable delivery vehicle.

18 . The method of claim 16 , wherein said delivery vehicle is a buffered saline solution, viscous solution, putty, paste, or gel.

19 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are directly injected into the site of implantation.

20 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are provided in a composition in a pre-loaded syringe for injecting into the joint or surgical site.

21 . The method of any one of the foregoing claims, wherein said hydrogel microparticles are confined to said site of implantation for a therapeutically effective period of time.

22 . The method of any one of the foregoing claims, wherein said hydrogel microparticles remain at said site of implantation without degradation under normal physiological conditions for at least 3 months.

23 . The method of any one of the foregoing claims, wherein said hydrogel microparticles remain at said site of implantation without degradation under normal physiological conditions for at least 6 months.

24 . The method of any one of the foregoing claims, wherein said human or animal subject received recurring dosages of said hydrogel microparticles administered at an interval of every 3 months, preferably every 3-6 months, preferably every 6-12 months.

25 . A kit for viscosupplementation in a joint or surgical site of a human or animal subject, comprising a plurality of porous viscoelastic solid hydrogel microparticles having a size of greater than about 30 μm, and substantially free of any cells, tissue, or therapeutic compounds, and instructions for administering the same.

26 . The kit of claim 25 , wherein said plurality of porous viscoelastic solid hydrogel microparticles are lyophilized, said kit further comprising a biologically compatible vehicle in a separate container for reconstituting said hydrogel microparticles or instructions for reconstituting said hydrogel microparticles prior to administration.

27 . The kit of claim 26 , further comprising an empty syringe and instructions for loading said syringe with said hydrogel microparticles after reconstitution.

28 . The kit of claim 25 , wherein said plurality of porous viscoelastic solid hydrogel microparticles are packaged in solution, wherein said solution is pre-loaded into a syringe for administration and instructions for the same.

29 . The kit of claim 25 , wherein said plurality of porous viscoelastic solid hydrogel microparticles are packaged in solution wherein said kit comprises an empty syringe and said hydrogel microparticles in a separate container configured to permit withdrawal of the solution from the container to load said syringe prior to said administration, and instructions for the same.

30 . A viscosupplement for use in treating a joint or surgical site of a human or animal subject such as by lubricating and cushioning intra-articular joint surfaces and tissues, comprising a plurality of porous viscoelastic solid hydrogel microparticles having a size of greater than about 30 μm, and substantially free of any cells, tissue, or therapeutic compounds, wherein said viscosupplement is configured for introduction into a joint or surgical site of the human or animal subject.

31 . A viscosupplement for use according to claim 30 , wherein the plurality of porous viscoelastic solid hydrogel microparticles are dispersed in a pharmaceutically-acceptable vehicle.

32 . Use of a viscosupplement in treating a joint or surgical site of a human or animal subject such as by lubricating and cushioning intra-articular joint surfaces and tissues, comprising a plurality of porous viscoelastic solid hydrogel microparticles having a size of greater than about 30 μm, and substantially free of any cells, tissue, or therapeutic compounds.

Assignments (2)
MERGER AND CHANGE OF NAME Recorded Jan 8, 2025
From: LIKARDA, LLC; LIKARDA, INC.
To: LIKARDA, INC.
Reel/Frame 069847/0885 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 20, 2023
From: HAMILTON, MEGAN E.; HARRINGTON, STEPHEN; RAMACHANDRAN, KARTHIK; STEHNO-BITTEL, LISA
To: LIKARDA, LLC
Reel/Frame 064967/0019 →